Advances in follicle stimulating hormone receptor and its targeted drugs / 肿瘤
Tumor
;
(12): 863-867, 2014.
Artigo
em Chinês
| WPRIM
| ID: wpr-848872
ABSTRACT
Follicle stimulating hormone receptor (FSHR) belongs to the G protein-coupled receptor family and is only low-expressed in reproductive organs of mammals. Recent studies have shown that FSHR is overexpressed in vascular endothelium of multiple types of human tumors including prostate cancer, breast cancer, liver cancer and kidney cancer, etc, and it plays an important role in the progression of cancer. Thus, FSHR is a potential target for diagnosis and treatment of tumors. Development of drugs targeting FSHR is beneficial to diagnosis, targeted therapy, selection of individualized drug therapy and prognosis of tumors. This paper summarizes the advances in FSHR and its specific ligands.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Tumor
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS